Historical Valuation
Lifecore Biomedical Inc (LFCR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 2.24 is considered Overvalued compared with the five-year average of -70.24. The fair price of Lifecore Biomedical Inc (LFCR) is between 4.54 to 7.06 according to relative valuation methord. Compared to the current price of 7.77 USD , Lifecore Biomedical Inc is Overvalued By 10.07%.
Relative Value
Fair Zone
4.54-7.06
Current Price：7.77
10.07%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Lifecore Biomedical Inc (LFCR) has a current Price-to-Book (P/B) ratio of 214.51. Compared to its 3-year average P/B ratio of 47.69 , the current P/B ratio is approximately 349.82% higher. Relative to its 5-year average P/B ratio of 29.30, the current P/B ratio is about 632.21% higher. Lifecore Biomedical Inc (LFCR) has a Forward Free Cash Flow (FCF) yield of approximately -4.70%. Compared to its 3-year average FCF yield of -13.17%, the current FCF yield is approximately -64.32% lower. Relative to its 5-year average FCF yield of -12.48% , the current FCF yield is about -62.37% lower.
P/B
Median3y
47.69
Median5y
29.30
FCF Yield
Median3y
-13.17
Median5y
-12.48
Competitors Valuation Multiple
AI Analysis for LFCR
The average P/S ratio for LFCR competitors is 1.49, providing a benchmark for relative valuation. Lifecore Biomedical Inc Corp (LFCR.O) exhibits a P/S ratio of 2.24, which is 50.76% above the industry average. Given its robust revenue growth of 25.92%, this premium appears sustainable.
Performance Decomposition
AI Analysis for LFCR
1Y
3Y
5Y
Market capitalization of LFCR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of LFCR in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is LFCR currently overvalued or undervalued?
Lifecore Biomedical Inc (LFCR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 2.24 is considered Overvalued compared with the five-year average of -70.24. The fair price of Lifecore Biomedical Inc (LFCR) is between 4.54 to 7.06 according to relative valuation methord. Compared to the current price of 7.77 USD , Lifecore Biomedical Inc is Overvalued By 10.07% .
What is Lifecore Biomedical Inc (LFCR) fair value?
LFCR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Lifecore Biomedical Inc (LFCR) is between 4.54 to 7.06 according to relative valuation methord.
How does LFCR's valuation metrics compare to the industry average?
The average P/S ratio for LFCR's competitors is 1.49, providing a benchmark for relative valuation. Lifecore Biomedical Inc Corp (LFCR) exhibits a P/S ratio of 2.24, which is 50.76% above the industry average. Given its robust revenue growth of 25.92%, this premium appears sustainable.
What is the current P/B ratio for Lifecore Biomedical Inc (LFCR) as of Jan 09 2026?
As of Jan 09 2026, Lifecore Biomedical Inc (LFCR) has a P/B ratio of 214.51. This indicates that the market values LFCR at 214.51 times its book value.
What is the current FCF Yield for Lifecore Biomedical Inc (LFCR) as of Jan 09 2026?
As of Jan 09 2026, Lifecore Biomedical Inc (LFCR) has a FCF Yield of -4.70%. This means that for every dollar of Lifecore Biomedical Inc’s market capitalization, the company generates -4.70 cents in free cash flow.
What is the current Forward P/E ratio for Lifecore Biomedical Inc (LFCR) as of Jan 09 2026?
As of Jan 09 2026, Lifecore Biomedical Inc (LFCR) has a Forward P/E ratio of -9.21. This means the market is willing to pay $-9.21 for every dollar of Lifecore Biomedical Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Lifecore Biomedical Inc (LFCR) as of Jan 09 2026?
As of Jan 09 2026, Lifecore Biomedical Inc (LFCR) has a Forward P/S ratio of 2.24. This means the market is valuing LFCR at $2.24 for every dollar of expected revenue over the next 12 months.